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In the United States, there were an estimated 146 970 new cases of 
colorectal cancer diagnosed, resulting in 49 920 deaths or a death-
to-diagnosis ratio of 34 to 100 in 2006 (1). Of those diagnosed, 
approximately 15 000 colorectal cancer cases were expected to 
occur in individuals of African ancestry (African American or black 
patients) and are expected to result in nearly 7000 deaths or a 47 
to 100 death-to-diagnosis ratio over the patients’ lifetimes (1). 
Although survival outcomes in the US colorectal cancer popula-
tion have improved in recent years, the disparity in survival 
between blacks and whites has not declined and remains substan-
tial. The 5-year relative survival rates in the United States for black 
and white colorectal cancer patients during 1999–2005 were 57% 
and 68%, respectively (1). Higher death rates from colorectal can-
cer account for 25% of the disparity in cancer death rates between 
black and white women and 11% of the disparity between black 
and white men (1). Despite the identification of several putative 
causes for worse outcomes in blacks, which include more advanced 
cancer stage at diagnosis, lack of access to medical care, suboptimal 
treatment, and lower socioeconomic status, the reasons for this 
disparity remain poorly understood (2).
In addition to the above-mentioned reasons for lower survival 
rates in blacks, it has been proposed that colorectal cancer in black 
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 Background Among patients with resected colon cancer, black patients have worse survival than whites. We investigated 
whether disparities in survival and related endpoints would persist when patients were treated with identical 
therapies in controlled clinical trials.
 Methods We assessed 14 611 patients (1218 black and 13 393 white) who received standardized adjuvant treatment in 12 
randomized controlled clinical trials conducted in North America for resected stage II and stage III colon cancer 
between 1977 and 2002. Individual patient data on covariates and outcomes were extracted from the Adjuvant 
Colon Cancer ENdpoinTs (ACCENT) database. The endpoints examined in this meta-analysis were overall sur-
vival (time to death), recurrence-free survival (time to recurrence or death), and recurrence-free interval (time to 
recurrence). Cox models were stratified by study and controlled for sex, stage, age, and treatment to determine 
the effect of race. Kaplan–Meier estimates were adjusted for similar covariates to control for confounding. All 
statistical tests were two-sided.
 Results Black patients were younger than whites (median age, 58 vs 61 years, respectively; P < .001) and more likely to 
be female (55% vs 45%, respectively; P < .001). Overall survival was worse in black patients than whites (hazard 
ratio [HR] of death = 1.22, 95% confidence interval [CI] = 1.11 to 1.34, P < .001). Five-year overall survival rates 
for blacks and whites were 68.2% and 72.8%, respectively. When subsets defined by sex, stage, and age were 
analyzed, overall survival was consistently worse in black patients. Recurrence-free survival was worse in black 
patients than whites (HR of recurrence or death = 1.14, 95% CI = 1.04 to 1.24, P = .0045). Three-year recurrence-
free survival rates in blacks and whites were 68.4% and 72.1%, respectively. In contrast, recurrence-free interval 
was similar in black and white patients (HR of recurrence = 1.08, 95% CI = 0.97 to 1.19, P = .15). Three-year 
recurrence-free interval rates in blacks and whites were 71.3% and 74.2%, respectively.
 Conclusions Black patients with resected stage II and stage III colon cancer who were treated with the same therapy as white 
patients experienced worse overall and recurrence-free survival, but similar recurrence-free interval, compared 
with white patients. The differences in survival may be mostly because of factors unrelated to the patients’ 
adjuvant colon cancer treatment.
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patients is less responsive to treatment because of a number of 
genetic factors related to both tumor characteristics in this popula-
tion and to ethnicity-based differences in pharmacogenetics that 
lead to disparate activity and toxicities of chemotherapy agents (3). 
However, race, in and of itself, may not be important in deter-
mining the prognosis of patients diagnosed with colorectal cancer. 
It is possible that by adjusting for comorbid conditions and socio-
economic factors associated with race, the poor survival outcome 
observed for black patients may be better understood and then 
either moderated or eliminated. In this study, we examined sur-
vival among black and white patients participating in adjuvant 
phase III cooperative group trials of resected colon cancer with 
data from the Adjuvant Colon Cancer ENdpoinT (ACCENT) 
collaborative group database (4–15). The cooperative group trial 
design defines the extent of disease at study entry and provides for 
uniform therapy, thus controlling for two major confounding fac-
tors affecting prognosis and allowing for other determinants of 
prognosis to be investigated.
The mandate of the National Institutes of Health Revitalization 
Act of 1993 required that all National Institutes of Health–
sponsored clinical trials (including cancer cooperative group trials) 
include minorities and women in sufficient numbers to allow valid 
subset analysis to ascertain differences in a treatment’s effect 
among women and minority participants (16). Our present analysis 




We analyzed data from 14 611 individual patients on 12 phase III 
randomized controlled clinical trials conducted in North America 
from 1977 to 2002 for adjuvant colon cancer (4–15). These trials 
provided standardized adjuvant treatment following resection of 
the primary tumor for these patients. Subsequent treatment in the 
event of recurrent disease was outside the scope of these studies 
and was not controlled by the study protocols; neither were data 
collected on salvage therapy. Our data come from the ACCENT 
collaborative group database. ACCENT is an international collab-
oration of colon cancer researchers who have pooled outcome data 
to better answer difficult questions related to our research. We 
included all trials from the database that had the following data 
available: treatment group, age, stage of disease (II or III), sex, time 
and censoring variables for our three endpoints (overall survival 
[time to death], recurrence-free survival [time to recurrence or 
death], and recurrence-free interval [time to recurrence]), and race 
(black or white). The analysis was restricted to patients with stage 
II and III disease and patients with race self-reported as black or 
white. A shortcoming of this database for the purpose of the pre-
sent analysis is that it does not include data on toxicity or comorbid 
conditions.
Trials Included
Table 1 provides a summary of the ACCENT adjuvant trials in-
cluded in this analysis. All included studies were approved by insti-
tutional review committees in accordance with the Helsinki 
Declaration. Written informed consent was obtained from all 
included participants. Dignam et al. (17) published a similar 
analysis of disparities in outcome by race on 6632 patients from 
five National Surgical Adjuvant Breast and Bowel Project (NSABP) 
studies in 1999; patients were a subset of the current study. A sim-
ilar study based on participants from Eastern Cooperative 
Oncology Group trials was published in 2002, with largely similar 
findings (18).
Statistical Analysis
Endpoints evaluated included overall survival (determined from 
time of study entry until death from any cause), recurrence-free 
survival (determined from the time of study entry until disease 
recurrence or death from any cause), and recurrence-free interval 
(determined from the time of study entry until disease recurrence 
but censoring for death before recurrence). The meta-analysis of 
data from the included trials was accomplished by multivariable 
Cox proportional hazard models (19) stratified by study. The Cox 
models were used to determine the hazard ratio (HR) and associ-
ated 95% confidence interval (CI) for race and to test for statistical 
significance after controlling for potential confounding because of 
sex, stage, age, or treatment type. The HR for race is calculated as 
the hazard of the event of interest (death for overall survival, recur-
rence or death for recurrence-free interval, and recurrence for 
CONTEXT AND CAVEATS
Prior knowledge
During 1999–2005, the 5-year relative survival rates for black and 
white colorectal cancer patients were 57% and 68%, respectively, in 
the United States. The disparity in survival between black and 
white patients remains substantial, and the reasons for disparity 
are still not well understood.
Study design
Data were obtained from the Adjuvant Colon Cancer ENdpoinTs 
(ACCENT) collaborative group database to analyze time-to-event 
endpoints for black and white patients participating in 12 random-
ized controlled adjuvant phase III trials of resected stage II and III 
colon cancer. The endpoints were overall survival (time to death), 
recurrence-free survival (time to recurrence or death), and recur-
rence-free interval (time to recurrence). Statistical models were 
stratified by study and controlled for sex, stage, age, and 
treatment.
Contribution
Black patients showed a worse 5-year overall survival rate com-
pared with white patients. Recurrence-free survival was also worse 
in black patients, but the recurrence-free interval was similar in 
black and white patients.
Implication
The disparity in overall survival and recurrence-free survival 
between black and white patients is not explained by differential 
response to adjuvant treatment.
Limitation
ACCENT database has no information on toxicity, comorbid condi-
tions, and treatment for recurrent disease, thereby limiting the 
analysis on disparities in outcomes associated with race.
From the Editors
 
1500   Articles | JNCI Vol. 103, Issue 20  |  October 19, 2011
recurrence-free interval) in black patients divided by the hazard of 
the event of interest in white patients so that values less than one 
favor blacks and values greater than one favor whites. Tests for 
interaction of the effect of race with individual prognostic covari-
ates in the model were accomplished by sequentially adding race–
covariate interaction terms to the model above and testing for 
statistical significance of the interaction in the Cox model. The 
lone exception to this pattern of interaction testing was for treat-
ment, where to limit complexity, the test was restricted to the three 
studies comparing surgery alone to chemotherapy [INT 0035 (5), 
NSABP C-01 (9), and NSABP C-02 (10)]. Possible heterogeneity 
of the effect of race across studies was tested by evaluating the 
race–study interaction terms in a Cox model where the interaction 
terms and terms for individual studies were added to the model 
instead of stratifying for study. The proportional hazards assump-
tion for the variable of interest for statistical inference in each 
model was tested by the method of Grambsch and Therneau (20). 
Kaplan–Meier estimates were adjusted for study, sex, stage, age, 
and type of treatment using the Xie and Liu method (21) to control 
for possible confounding from these prognostic factors. All P 
values are two-sided and values less than .05 are considered statis-
tically significant.
Results
Among the 14 611 patients included in this analysis, 1218 (8.3%) 
described themselves as black. The distribution of treatment and 
patient and/or tumor characteristics by race for all patients is 
shown in Table 2. Black patients were younger than white patients 
(median age, 58 [range 17–85 years] vs 61 years [range 15–90 
years], respectively, P < .01) and more likely to be female (55% vs 
45%, P < .01). There was a borderline statistically significant dif-
ference between blacks and whites by stage of disease (35% stage 
II in blacks vs 33% in whites, P = .069). There were racial differ-
ences in the distribution of treatments received (P < .01) because 
of different rates of black patient participation among the trials 
studied, but treatments were balanced by race within individual 
studies. To control for these observed differences in the distribution 
of covariates by race, subsequent analyses adjusted for differences 
in sex, stage, age, and treatment type.
We began analysis by verifying that the effect of race on our 
three endpoints did not vary by treatment, by prognostic covari-
ates, or by included study. There was no evidence that the effect of 
treatment differed by race in the three studies [INT 0035 (5), 
NSABP C-01 (9), and NSABP C-02 (10)] that compared surgery 
alone to surgery plus 5-fluorouracil (5-FU)–based chemotherapy 
(race–treatment interaction: for overall survival, Pinteraction = .76; for 
recurrence-free survival, Pinteraction = .85; and for recurrence-free 
interval, Pinteraction = .51). Across all studies (4–15), there was no 
strong evidence that the effect of race varied by stage of disease 
(race–stage interaction: for overall survival, Pinteraction = .97; for 
recurrence-free survival, Pinteraction = .80; and for recurrence-free 
interval, Pinteraction = .37); by sex (race–sex interaction: for overall 
survival, Pinteraction = .49; for recurrence-free survival, Pinteraction = .49; 
and for recurrence-free interval, Pinteraction = .15), or by age (race–age 
interaction: for overall survival, Pinteraction = .38; for recurrence-free 
survival, Pinteraction = 0.40; and for recurrence-free interval, Pinteraction = 
.18). The hazard ratios (black divided by white) for overall survival 
Table 1. ACCENT studies included in the analysis*
Study† (reference) No.
Race, % Treatment type, %
White Black Surgery alone 5-FU or MOF 5-FU + LV or LEV
5-FU + LV + oxaliplatin 
or irinotecan
CALGB 89803 (4) 1176 92.9 7.1   49.4 50.6
INT 0035 (5) 849 93.2 6.8 51.1  48.9
NCCTG 894651 (6) 814 97.1 3.0   100.0
NCCTG 914653 (7) 607 96.9 3.1   100.0
S9415 (8) 906 90.9 9.1   100.0
NSABP C-01 (9) 965 81.9 18.1 68.2 31.8  
NSABP C-02 (10) 646 90.6 9.4 49.9 50.1  
NSABP C-03 (11) 988 91.2 8.8  50.2 49.8
NSABP C-04 (12) 1979 91.8 8.2   100.0
NSABP C-05 (13) 1999 91.5 8.5   100.0
NSABP C-06 (14) 1457 91.4 8.6   100.0
NSABP C-07 (15) 2225 92.4 7.6   50.6 49.4
Total‡ 14611 91.7 8.3 9.7 7.7 71.0 11.6
* ACCENT = Adjuvant Colon Cancer ENdpoinT; CALGB = Cancer and Leukemia Group B; INT = Intergroup; MOF = methyl-(CCNU) + vincristine (Oncovin) + 5-FU; 
LEV = levamisole; LV = leucovorin; NCCTG = North Central Cancer Treatment Group; S = Southwest Oncology Group; NSABP = National Surgical Adjuvant 
Breast and Bowel Project; 5-FU = 5-fluorouracil.
† CALGB 89803 was a negative study evaluating the addition of Irinotecan to 5-FU + LV in stage III colon cancer. INT 0035 showed the superiority of 5-FU + LEV 
for disease-free survival compared with surgery alone. NCCTG 894651 compared 5-FU + LEV and 5-FU + LEV + LV both given for 6 and 12 months and found 6 
months of 5-FU + LEV + LV equivalent to 12 months of 5-FU + LEV. NCCTG 914653 was a negative trial evaluating dose escalation of LEV along with 5-FU + LV 
compared with standard 5-FU + LEV + LV. S9415 compared infusional 5-FU + LEV to bolus 5-FU + LEV + LV and found similar efficacy with reduced toxicity for 
the infusional regimen. NSABP C-01 was a three-arm trial comparing surgery alone to Bacillus Calmette-Guérin immunotherapy (no difference in cancer out-
comes) and to 5-FU, semustine, and vincristine (MOF) (MOF superior). NSABP C-02 found an advantage to infusional 5-FU over surgery alone. NSABP C-03 found 
5-FU + LV superior to MOF. NSABP C-04 compared three arms 5-FU + LV, 5-FU + LEV, and 5-FU + LEV + LV and found 5-FU + LV superior to 5-FU + LEV with 
the three-drug regimen equivalent to 5-FU + LV. NSABP C-05 was a negative trial investigating the addition of interferon alpha to 5-FU + LV. NSABP C-06 found 
Uracil/Ftorafur equivalent to 5-FU + LV. NSABP C-07 showed that the addition of oxaliplatin to 5-FU + LV improved outcomes.
‡ Total is sum of number of patients for individual trials or the percentage of patients from all studies pooled.
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interval (time to recurrence censoring for death without recur-
rence) did not differ statistically significantly by race (4734 recur-
rences, HR of recurrence = 1.08, 95% CI = 0.97 to 1.19, P = .15). 
The 3-year adjusted Kaplan–Meier estimates of recurrence-free 
interval rates for black vs white patients were 71.3% vs 74.2%, 
respectively (data not shown in table or figure). This analysis had 
76% power to detect a hazard ratio of 1.15 for recurrence-free 
interval (roughly equivalent to a 3.2% detriment for blacks in 
3-year recurrence-free interval assuming 72.4% recurrence-free 
interval for whites; survival follows an exponential distribution).
Discussion
In this cohort of 14 611 colon cancer patients treated on clinical 
trials of adjuvant chemotherapy, 1218 patients were black and 
13 393 patients were white. We analyzed individual patient data 
from 12 clinical trials included in the ACCENT collaborative 
database. We found statistically significantly shorter overall sur-
vival for black patients compared with white patients with a 4.6% 
detriment in 5-year survival. Recurrence-free survival was also 
statistically significantly shorter for black patients compared with 
white patients with a 3.7% detriment in 3-year outcomes. Finally, 
we found no statistically significant difference in recurrence-free 
interval (time to recurrence) with a non-statistically significant 
detriment of 2.9% observed for 3-year outcomes.
The aim of adjuvant chemotherapy for colon cancer is to extend 
patient survival by delaying or preventing recurrence of colon 
cancer. Of the three endpoints considered in this analysis, recur-
rence-free interval (time to recurrence) is the most sensitive 
measure of the intended effect of chemotherapy. Unlike overall 
and recurrence-free survival, this endpoint would not be biased as 
a result of disparity in treatment for recurrent colon cancer, dispa-
rate care for comorbid conditions, or differential rates of death 
from causes unrelated to colon cancer. In this study, recurrence-
free interval for black and white patients did not differ statistically 
significantly by race (HR of recurrence = 1.08, 3-year difference 
2.9%, 4734 recurrences). The similar outcomes for recurrence-
free interval suggest that equivalent treatment in the setting of a 
controlled clinical trial produces similar outcomes in both black 
and white patients with regard to tumor recurrence. Any differen-
tial response to adjuvant chemotherapy must be small.
The second endpoint considered in this study was recurrence-
free survival (time to recurrence or death). In this analysis, black 
patients were found to have slightly worse recurrence-free survival 
compared with white patients (HR of recurrence or death = 1.14, 
3-year difference 3.7%, 6231 events [recurrences or deaths]). 
Every patient who has an event (recurrence) for recurrence-free 
interval also has an event for recurrence-free survival; however, 
patients who die without recurrence are counted as an event for 
recurrence-free survival but not recurrence-free interval. These 
additional deaths (which were not preceded by recurrence, N = 
6231–4734 = 1497) are likely unrelated to colon cancer and un-
likely to be affected by adjuvant chemotherapy. Racial differences 
in comorbidity or general life expectancy are potential explanations 
for the statistically significant difference observed on this endpoint. 
Because life expectancy differs by race independent of a cancer 
diagnosis (22), it is reasonable to conclude that some of the disparity 
(Figure 1, A), recurrence-free survival (Figure 1, B), and recur-
rence-free interval (Figure 1, C) show that there was no evidence 
of heterogeneity of the effect of race across studies for any of these 
endpoints analyzed (race–study interaction: for overall survival, 
Pinteraction = .59; for recurrence-free survival, Pinteraction = .41; and for 
recurrence-free interval, Pinteraction = .71). We next analyzed the ef-
fect of race on our three endpoints after stratifying for study and 
controlling for sex, stage, age, and treatment type. All Kaplan–
Meier estimates are adjusted for study, sex, stage, age, and type of 
treatment to control for possible confounding from these factors. 
As shown in the adjusted Kaplan–Meier plots of overall survival by 
race (Figure 2, A), overall survival (time to death from any cause) 
in black patients was worse than in white patients (5539 deaths, 
HR of death = 1.22, 95% confidence interval [CI] = 1.11 to 1.34, 
P < .001). Table 3 shows the results from Cox models testing the 
effect of race on our three endpoints. The 5-year adjusted Kaplan–
Meier estimates of survival rates for black vs white patients were 
68.2% vs 72.8%, respectively (data not shown in table or figure). 
Overall survival was consistently worse in black patients in subsets 
defined by sex, stage, and age (data not shown). As shown in the 
adjusted Kaplan–Meier plots of recurrence-free survival by race 
(Figure 2, B), recurrence-free survival (time to recurrence or death 
without recurrence) results were attenuated compared with overall 
survival, but recurrence-free survival remained statistically signifi-
cantly worse in black patients (6231 events, HR of recurrence or 
death = 1.14, 95% CI = 1.04 to 1.24, P = .0045). The 3-year ad-
justed Kaplan–Meier estimates of recurrence-free survival rates for 
black vs white patients were 68.4% vs 72.1%, respectively (data not 
shown in table or figure). As shown in the adjusted Kaplan–Meier 
plots of recurrence-free interval by race (Figure 2, C), recurrence-free 
Table 2. Patient and tumor characteristics of patients included in 
the analysis*
Category
White patients,  
% (N = 13 393)
Black patients,  
% (N = 1218) P†
Cancer stage‡   
 II 32.6 35.1 .069
 III 67.4 64.9
Sex   
 Women 45.0 54.7 <.01
 Men 55.0 45.3
Age, y   
 <40 5.5 7.6 <.01
 40–49 12.6 15.4
 50–59 26.9 32.6
 60–69 37.4 32.3
 ≥70 17.6 12.2
Treatment   
 Surgery alone 9.3 14.4 <.01
 5-FU or MOF 7.4 10.8
 5-FU + LV or LEV 71.7 64.0
 5-FU + LV +  
  oxaliplatin/irinotecan
11.7 10.8
* LEV = levamisole; LV = leucovorin; MOF = methyl-(CCNU) and vincristine 
(Oncovin) and 5-FU; 5-FU = 5-fluorouracil.
† P values were calculated using a two-sided x2 test.
‡ Stage II: tumor penetrates beyond the muscularis propria but no lymph node 
invasion and no other metastases. Stage III: lymph node invasion but no 
other metastases.
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Figure 1. Forest plots of hazard ratios (black divided by white) for 
death (overall survival [OS]), recurrence or death (recurrence-free 
survival [RFS]), and recurrence (recurrence-free interval [RFI]). The 
vertical lines indicate a hazard ratio of 1.0 (no difference between 
black and white race), values less than 1.0 favor black patients, and 
values greater than 1.0 favor white patients. Solid rectangles repre-
sent the hazard ratio of each single randomized controlled trial; the 
area of each rectangle is proportional to the inverse of the variance of 
the estimate. The horizontal line represents the 95% confidence inter-
val and arrowheads indicate that the confidence interval extends 
beyond the scale of the plot. The solid diamonds represent the overall 
estimated hazard ratio based on multivariable Cox models of overall 
survival, recurrence-free survival, and recurrence-free interval con-
trolling for sex, stage, age, and treatment, either not controlling for 
study (pooled) or stratifying by study (stratified); the diamond’s width 
represents the 95% confidence interval of the hazard ratio. A) OS. B) 
RFS. C) RFI. CALGB = Cancer And Leukemia Group B; CI = confidence 
interval; INT = Intergroup; NCCTG = North Central Cancer Treatment 
Group; NSABP = National Surgical Adjuvant Breast and Bowel 
Project.
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in recurrence-free survival observed in this study is because of 
factors unrelated to adjuvant treatment for colon cancer.
Overall survival (time to death from any cause) was the final 
endpoint considered in this study. Despite similar stages of disease 
and equivalent adjuvant therapy, our analysis of the survival end-
point found a statistically significant difference by race with worse 
survival for black patients (HR of death = 1.22, 5-year difference 
4.6%, 5539 deaths) when compared with white patients. The over-
all survival endpoint includes the same 1497 deaths not preceded 
by recurrence (27% of all deaths) included as events for recur-
rence-free survival, and overall survival is similarly susceptible to 
confounding by racial differences in comorbidity or general life 
expectancy. Additionally, the remaining 4042 deaths (73% of all 
deaths) were preceded by recurrence, and time to death for these 
patients may have been impacted by salvage treatment for recur-
rent disease. Because treatment for recurrent disease was outside 
the research protocols of the studies included in this analysis, racial 
differences in care for recurrent disease are also a potential con-
founder of overall survival.
There was no heterogeneity of the effect of race across studies 
for any of the endpoints considered. The effect of 5-FU treatment 
appears to be similar by race for the endpoints considered. The 
effect of race was also similar for our three endpoints by stage of 
disease, sex, and age.
Colorectal cancer remains a leading cause of cancer-related 
deaths in the United States. Across all stages of disease, survival for 
black patients continues to lag behind that reported for nonblack 
patients (1). There have been a number of potential reasons pro-
posed for this observation including later stage at diagnosis, differ-
ences in treatment, and the postulate that black patients have a 
biologically more aggressive disease or have a poorer response to 
currently used chemotherapy agents. Although these factors are 
important in patient outcome, perhaps the most relevant hypo-
thesis is that African American patients are less likely to have access 
to routine cancer care, resulting in a poorer patient condition (eg, 
greater weight loss and poorer performance status) and later stage 
at diagnosis. In support of this postulate are data from the Black/
White Cancer Survival Study Group (23–27). Using the ACCENT 
Figure 2. Kaplan–Meier estimates adjusted by the method of Xie and Liu (21) for study, sex, stage, age, and type of treatment. A) Overall survival. 
B) Recurrence-free survival. C) Recurrence-free interval. Life tables for the number of patients at risk are presented below each graph. In a matrix 
within each graph, the number of patients and events are provided by race along with the hazard ratio and P value from a multivariable Cox model 
stratified by study and controlling for sex, stage, age, and treatment. The P values come from the two-sided Wald test.
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clinical trial database, we have attempted to investigate this hypo-
thesis. The ACCENT adjuvant colon cancer database offers sev-
eral advantages over the use of other data sources. First, stage of 
disease is comparable within the constraints of the protocol entry 
criteria. Second, treatment and follow-up care are conducted 
according to a uniform standard.
This study has a few limitations. The ACCENT database does 
not include data on toxicity, comorbid conditions, and treatment for 
recurrent disease. The lack of these important data hinders our inves-
tigation of some important questions related to disparities in out-
comes. Black vs white race is clearly not a randomized comparison, 
so we are forced to attempt to control for as many potentially prog-
nostic covariates as possible to avoid a biased comparison by race.
The reason for the inferior overall survival for the black 
patients in this analysis warrants further consideration. In addition 
to the potential for noncancer deaths to contribute to differences 
in overall survival, the literature would support the notion that 
black patients may have a genetically unique response or toxicity to 
treatment compared with white patients. In the adjuvant trials in-
cluded in this analysis, all patients receiving chemotherapy were 
treated with 5-FU either alone or in combination with other 
agents. 5-FU must first be activated by binding to methylenetetra-
hydrofolate reductase (MTHFR), a cellular molecule present at 
varying concentrations among patients(28). It is known that the 
MTHFR gene has several polymorphisms among populations, dif-
ferent MTHFR polymorphisms confer different levels of sensi-
tivity to chemotherapy (28), and that the polymorphisms are 
influenced by race. In a related finding, the pharmacogenetic 
syndrome, dihydropyrimidine dehydrogenase (DPD) deficiency, 
has been shown to predispose cancer patients to severe 5-FU tox-
icity (29). As reported by Mattison et al. (30), the prevalence of 
DPD deficiency was threefold higher in black healthy volunteers 
when compared with white volunteers; 8.0% and 2.8%, respec-
tively. An analysis of 1402 patients receiving chemotherapy for 
metastatic colorectal cancer (3) found that black patients had a 
different frequency of polymorphisms in key genes coding for 
Table 3. Multivariable Cox models stratified by study*
Factor No.
OS RFS RFI






<.001 II 4792 1.00 (referent) 1.00 (referent) 1.00 (referent)






0.27 Women 6697 1.00 (referent) 1.00 (referent) 1.00 (referent)







 <50 2708 1.00 (referent) 1.00 (referent) 1.00 (referent)
 50–59 3996 1.14 (1.04 to 1.24) 1.09 (1.00 to 1.18) 1.00 (0.91 to 1.08)






0.15 White 13 393 1.00 (referent) 1.00 (referent) 1.00 (referent)
 Black 1218 1.22 (1.11 to 1.34) 1.14 (1.04 to 1.24) 1.08 (0.97 to 1.19)
* Multivariable analyses of OS, RFS, and RFI stratified by study and controlling for sex, stage, age, and treatment (data for treatment not shown) to determine the 
effect of race. CI = confidence interval; HR = hazard ratio; OS = overall survival; RFS = recurrence-free survival; RFI = recurrence-free interval.
† P values were calculated using a two-sided Wald test.
‡ Stage II: tumor penetrates beyond the muscularis propria but no lymph node invasion and no other metastases. Stage III: lymph node invasion but no other 
metastases.
enzymes involved in drug activation, metabolism, and disposition. 
The unavailability of toxicity data for the current analysis limits 
our ability to explore this question fully, but the similarities of 
recurrence-free interval outcomes by race suggest similar response 
to adjuvant chemotherapy.
The ability for patients to receive or to respond to salvage che-
motherapy and/or surgery subsequent to recurrence could clearly 
impact on overall survival without affecting recurrence-free inter-
val. The disparity in access to medical care between black and 
white patients is real (31) but incompletely understood. Further 
study is warranted with the goal of improving overall survival in 
black patients with stage II and III colon cancer.
Black patients with resected stage II and III colon cancer 
treated with identical adjuvant therapy experienced poorer overall 
and recurrence-free survival but similar recurrence-free interval 
compared with white patients. The overall and recurrence-free 
survival endpoints include deaths not preceded by cancer recur-
rence and likely unrelated to colon cancer. This suggests that 
overall and recurrence-free survival differences may be largely 
because of factors unrelated to the patients’ adjuvant colon cancer 
treatment. Biological differences, differences in general health, 
and disparities in health care outside the clinical trial are possible 
explanations for these findings but will need to be pursued in other 
studies where data on patient care for recurrent cancer or comor-
bid conditions are available.
Appendix
The Adjuvant Colon Cancer ENdpoinT (ACCENT) Collaborative Group con-
sists of D. J. Sargent, E. Green, A. Grothey, S. R. Alberts, B. Bot, M. Campbell, 
Q. Shi (Mayo Clinic, Rochester, MN); G. Yothers, M. J. O’Connell, N. Wolmark 
(National Surgical Adjuvant Breast and Bowel Project Biostatistical and Operations 
Centers, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA [NW]); A. 
de Gramont (Hôpital Saint Antoine, Paris, France); R. Gray, D. Kerr (QUASAR 
Collaborative Group, Birmingham and Oxford, UK); D. G. Haller (Abramson 
Cancer Center at the University of Pennsylvania, Philadelphia, PA); J. Benedetti 
(Southwest Oncology Group Statistical Center, Seattle, WA); M. Buyse 
(International Drug Development Institute, Louvain-la-Neuve, Belgium); 
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